Systematic Reviews
Copyright ©The Author(s) 2018.
World J Gastroenterol. Jul 21, 2018; 24(27): 3038-3054
Published online Jul 21, 2018. doi: 10.3748/wjg.v24.i27.3038
Table 5 Hepatitis C antibody incidence and/or sero-conversion risk rate relative to the total sample size, and evidence gap mapping, Middle East and North Africa
CountrySystematic reviewLiterature search periodNumber of studies identifiedNumber of subjectsPopulation typeEstimation time periodHCV incidence rate (per 1000 person-year)Loss of follow-upHCV sero-conversion risk (%)Duration of follow-up
IraqChemaitelly, 2015[33]1985-2015157Hemodialysis patients2009-040.312 mo
Chemaitelly, 2015[33]1985-20151123Pediatric patients with acute lymphoblastic leukemia2007-03.230 mo (median)
Chemaitelly, 2015[33]1985-2015126Newborn to HCV infected women--006 mo
Chemaitelly, 2015[33]1985-2015185Pediatric cancer patients on chemotherapy2006-2007-223.212 mo
Chemaitelly, 2015[33]1985-2015160Healthy children2007-2009-006 mo
Chemaitelly, 2015[33]1985-2015129Pediatric patients with leukemia on chemotherapy2007-2009-03.56 mo
Chemaitelly, 2015[33]1985-2015127Pediatric patients with leukemia who have had their baseline screening prior to chemotherapy2007-2009-006 mo
LebanonChemaitelly, 2015[33]1985-201500
PalestineChemaitelly, 2015[33]1985-201500
JordanChemaitelly, 2015[33]1985-201511300Hemodialysis patients2003--9.212 mo
SyriaBashour, 2016[91]Unknown00
Sievert, 2011[50]Unknown00
United Arab EmiratesMohamoud, 2016[59]Unknown1-Hemodialysis patients1995108---
YemenChaabna, 2016[27]Inception-201500